Yehia Richael, Ph.D.

CEO & Director

Yehia Richael is co-founder and CEO of CRC. A spin out from his research group at University College London in 1999. Yehia was the inventor of all CRC products including OncoCRC-CSF ( laherparepvec; Imlypar) and oversaw all research and clinical development including Imlypar bringing through to two pivotal phase 3 studies in melanoma and head & neck cancer. Yehia was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1994.